MedTrace Logo

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 781430

Last updated 2026-05-15

No results posted yet for this study

Summary

To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).

Conditions

Interventions

DRUG

SGLT2 inhibitor

Any SGLT2i dispensing claim

DRUG

DPP-4 inhibitor

Any DPP-4 inhibitor claim

DRUG

GLP-1RA

Any SGLT2i dispensing claim

DRUG

2nd generation SU

Any 2nd generation SU claim

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • VA Boston Healthcare System

    collaborator FED

  • McGill University

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Elisabetta Patorno, MD, DrPH · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2026-05-31
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05220917 on ClinicalTrials.gov